Cargando…
Characterisation of a novel transcript LNPPS acting as tumour suppressor in bladder cancer via PDCD5‐mediated p53 degradation blockage
BACKGROUND: Long non‐coding RNAs (lncRNAs) play a crucial role in tumour initiation and progression. However, little is known about their contributions to p53‐related bladder cancer (BC) inhibition. METHODS: By using high‐throughput sequencing, we screened the expression profiles of lncRNAs in BC an...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9797767/ https://www.ncbi.nlm.nih.gov/pubmed/36578176 http://dx.doi.org/10.1002/ctm2.1149 |
_version_ | 1784860754023809024 |
---|---|
author | Li, Juan Wang, Yifan Zhang, Xinya Yang, Xuemei Qi, Qiuchen Mi, Qi Feng, Maoxiao Wang, Yunshan Wang, Chuanxin Li, Peilong Du, Lutao |
author_facet | Li, Juan Wang, Yifan Zhang, Xinya Yang, Xuemei Qi, Qiuchen Mi, Qi Feng, Maoxiao Wang, Yunshan Wang, Chuanxin Li, Peilong Du, Lutao |
author_sort | Li, Juan |
collection | PubMed |
description | BACKGROUND: Long non‐coding RNAs (lncRNAs) play a crucial role in tumour initiation and progression. However, little is known about their contributions to p53‐related bladder cancer (BC) inhibition. METHODS: By using high‐throughput sequencing, we screened the expression profiles of lncRNAs in BC and adjacent non‐tumour tissues. The roles of a novel lncRNA, named LNPPS [a lncRNA for programmed cell death 5 (PDCD5) and p53 stability], were determined by gain‐ and loss‐of‐function assays. RNA pull‐down followed by mass spectrometry analysis, RNA immunoprecipitation assays and other immunoprecipitation assays were performed to reveal the interactions among LNPPS, PDCD5 and p53, and the regulatory effect of LNPPS on the complex ubiquitination network comprising PDCD5, p53 and mouse double minute 2 homologue (MDM2). RESULTS: LNPPS was downregulated in BC and markedly inhibited the viability of BC cells by inducing PDCD5/p53‐related apoptosis in vivo and in vitro. Mechanistically, LNPPS, serving as a scaffold, connected PDCD5 and p53 with nucleotides (nt) located at 121‒251 nt and 251‒306 nt of LNPPS, respectively. This process allowed LNPPS to protect PDCD5 from proteasomal degradation by blocking its K20 site ubiquitination. On the other hand, the increased interaction between PDCD5 and p53 displaced p53 from the MDM2‒p53 ubiquitination complex, resulting in an increase in p53 expression and related apoptosis levels. Moreover, LNPPS could induce the accumulation of PDCD5 and p53 in the nucleus and exert a synergistic effect on the prevention of protein degradation. In addition, we confirmed that the downregulation of LNPPS in BC was mediated by the decreased N6‐methyladenosine (m(6)A) modification. CONCLUSION: Our findings highlight a novel cross‐talk between LNPPS and the PDCD5/p53/MDM2 ubiquitination axis in BC development, indicating its potential as a therapeutic target for BC patients. |
format | Online Article Text |
id | pubmed-9797767 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97977672023-01-05 Characterisation of a novel transcript LNPPS acting as tumour suppressor in bladder cancer via PDCD5‐mediated p53 degradation blockage Li, Juan Wang, Yifan Zhang, Xinya Yang, Xuemei Qi, Qiuchen Mi, Qi Feng, Maoxiao Wang, Yunshan Wang, Chuanxin Li, Peilong Du, Lutao Clin Transl Med Research Articles BACKGROUND: Long non‐coding RNAs (lncRNAs) play a crucial role in tumour initiation and progression. However, little is known about their contributions to p53‐related bladder cancer (BC) inhibition. METHODS: By using high‐throughput sequencing, we screened the expression profiles of lncRNAs in BC and adjacent non‐tumour tissues. The roles of a novel lncRNA, named LNPPS [a lncRNA for programmed cell death 5 (PDCD5) and p53 stability], were determined by gain‐ and loss‐of‐function assays. RNA pull‐down followed by mass spectrometry analysis, RNA immunoprecipitation assays and other immunoprecipitation assays were performed to reveal the interactions among LNPPS, PDCD5 and p53, and the regulatory effect of LNPPS on the complex ubiquitination network comprising PDCD5, p53 and mouse double minute 2 homologue (MDM2). RESULTS: LNPPS was downregulated in BC and markedly inhibited the viability of BC cells by inducing PDCD5/p53‐related apoptosis in vivo and in vitro. Mechanistically, LNPPS, serving as a scaffold, connected PDCD5 and p53 with nucleotides (nt) located at 121‒251 nt and 251‒306 nt of LNPPS, respectively. This process allowed LNPPS to protect PDCD5 from proteasomal degradation by blocking its K20 site ubiquitination. On the other hand, the increased interaction between PDCD5 and p53 displaced p53 from the MDM2‒p53 ubiquitination complex, resulting in an increase in p53 expression and related apoptosis levels. Moreover, LNPPS could induce the accumulation of PDCD5 and p53 in the nucleus and exert a synergistic effect on the prevention of protein degradation. In addition, we confirmed that the downregulation of LNPPS in BC was mediated by the decreased N6‐methyladenosine (m(6)A) modification. CONCLUSION: Our findings highlight a novel cross‐talk between LNPPS and the PDCD5/p53/MDM2 ubiquitination axis in BC development, indicating its potential as a therapeutic target for BC patients. John Wiley and Sons Inc. 2022-12-28 /pmc/articles/PMC9797767/ /pubmed/36578176 http://dx.doi.org/10.1002/ctm2.1149 Text en © 2022 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Articles Li, Juan Wang, Yifan Zhang, Xinya Yang, Xuemei Qi, Qiuchen Mi, Qi Feng, Maoxiao Wang, Yunshan Wang, Chuanxin Li, Peilong Du, Lutao Characterisation of a novel transcript LNPPS acting as tumour suppressor in bladder cancer via PDCD5‐mediated p53 degradation blockage |
title | Characterisation of a novel transcript LNPPS acting as tumour suppressor in bladder cancer via PDCD5‐mediated p53 degradation blockage |
title_full | Characterisation of a novel transcript LNPPS acting as tumour suppressor in bladder cancer via PDCD5‐mediated p53 degradation blockage |
title_fullStr | Characterisation of a novel transcript LNPPS acting as tumour suppressor in bladder cancer via PDCD5‐mediated p53 degradation blockage |
title_full_unstemmed | Characterisation of a novel transcript LNPPS acting as tumour suppressor in bladder cancer via PDCD5‐mediated p53 degradation blockage |
title_short | Characterisation of a novel transcript LNPPS acting as tumour suppressor in bladder cancer via PDCD5‐mediated p53 degradation blockage |
title_sort | characterisation of a novel transcript lnpps acting as tumour suppressor in bladder cancer via pdcd5‐mediated p53 degradation blockage |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9797767/ https://www.ncbi.nlm.nih.gov/pubmed/36578176 http://dx.doi.org/10.1002/ctm2.1149 |
work_keys_str_mv | AT lijuan characterisationofanoveltranscriptlnppsactingastumoursuppressorinbladdercancerviapdcd5mediatedp53degradationblockage AT wangyifan characterisationofanoveltranscriptlnppsactingastumoursuppressorinbladdercancerviapdcd5mediatedp53degradationblockage AT zhangxinya characterisationofanoveltranscriptlnppsactingastumoursuppressorinbladdercancerviapdcd5mediatedp53degradationblockage AT yangxuemei characterisationofanoveltranscriptlnppsactingastumoursuppressorinbladdercancerviapdcd5mediatedp53degradationblockage AT qiqiuchen characterisationofanoveltranscriptlnppsactingastumoursuppressorinbladdercancerviapdcd5mediatedp53degradationblockage AT miqi characterisationofanoveltranscriptlnppsactingastumoursuppressorinbladdercancerviapdcd5mediatedp53degradationblockage AT fengmaoxiao characterisationofanoveltranscriptlnppsactingastumoursuppressorinbladdercancerviapdcd5mediatedp53degradationblockage AT wangyunshan characterisationofanoveltranscriptlnppsactingastumoursuppressorinbladdercancerviapdcd5mediatedp53degradationblockage AT wangchuanxin characterisationofanoveltranscriptlnppsactingastumoursuppressorinbladdercancerviapdcd5mediatedp53degradationblockage AT lipeilong characterisationofanoveltranscriptlnppsactingastumoursuppressorinbladdercancerviapdcd5mediatedp53degradationblockage AT dulutao characterisationofanoveltranscriptlnppsactingastumoursuppressorinbladdercancerviapdcd5mediatedp53degradationblockage |